Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin.
Yamamoto
K
K
Honda
T
T
Matsushita
T
T
Kojima
T
T
Takamatsu
J
J
D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D005167:Factor VII / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D006467:Hemophilia A / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D002836:Hemophilia B / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012254:Ribavirin / Q000494:pharmacology*
D000998:Antiviral Agents; D012333:RNA, Messenger; D012254:Ribavirin; D005167:Factor VII